Bayer (BAYN) Given a €100.00 Price Target at Barclays

Bayer (FRA:BAYN) received a €100.00 ($119.05) target price from research analysts at Barclays in a report issued on Wednesday. The firm presently has a “sell” rating on the healthcare company’s stock. Barclays’ price objective would indicate a potential downside of 4.08% from the company’s previous close.

BAYN has been the subject of a number of other research reports. UBS set a €125.00 ($148.81) price objective on Bayer and gave the stock a “buy” rating in a report on Tuesday, August 29th. S&P Global set a €126.00 ($150.00) target price on Bayer and gave the stock a “buy” rating in a research note on Thursday, October 26th. Sanford C. Bernstein set a €131.00 ($155.95) target price on Bayer and gave the stock a “buy” rating in a research note on Wednesday, November 29th. Independent Research set a €120.00 ($142.86) target price on Bayer and gave the stock a “neutral” rating in a research note on Wednesday, August 23rd. Finally, equinet set a €118.00 ($140.48) target price on Bayer and gave the stock a “buy” rating in a research note on Friday, October 13th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of €122.19 ($145.46).

Bayer (BAYN) opened at €104.25 ($124.11) on Wednesday. Bayer has a twelve month low of €86.60 ($103.10) and a twelve month high of €123.82 ($147.40).

ILLEGAL ACTIVITY NOTICE: “Bayer (BAYN) Given a €100.00 Price Target at Barclays” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://ledgergazette.com/2017/12/06/bayer-bayn-given-a-100-00-price-target-at-barclays.html.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply